REG - Cambridge Cognition - Commercialisation Agreement

Cambridge Cognition HoldingsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260216:nRSP0439Ta&default-theme=true

RNS Number : 0439T  Cambridge Cognition Holdings PLC  16 February 2026

16 February 2026

 

Cambridge Cognition partners with Ivory

to scale early cognitive screening with CANTAB Pathway™ in India

 

Bengaluru, India and Cambridge, United Kingdom: Cambridge Cognition Holdings
plc ("Cambridge Cognition") (AIM: COG), the neuroscience technology company
specialising in digital cognitive assessments, and Ivory, a venture-backed
brain health company headquartered in India, announce an agreement for the
commercialisation of CANTAB Pathway™ across the healthcare and consumer
health markets in India.

Highlights

·    Ivory will deploy CANTAB Pathway™ across both professional
healthcare and consumer health segments in India

·    Of India's population of approximately 1.47 billion, estimates
indicate that 138 million people are aged over 60, and as many as 34 million
may be living with mild or major cognitive impairment

·    India's middle and affluent class, estimated to be 90-190 million
people, is believed to have an increasing interest in longevity, healthspan,
and access to high-quality healthcare

 

This partnership represents an important strategic step in Cambridge
Cognition's expansion into high-growth international healthcare and consumer
markets, leveraging Ivory's rapidly scaling brain health platform and
distribution network.

India represents a significant growth opportunity with a population of
approximately 1.47 billion.  Recent research estimated that among India's 138
million people aged over 60, as many as 34 million may be living with mild or
major cognitive impairment (Gross et al., PLOS One, LASI-DAD study).

Rob Baker, Chief Executive Officer - Cambridge Cognition, said, "India
represents a major opportunity, with a significant unmet need for earlier
identification of cognitive impairment.  As health-conscious, tech-enabled
populations grow, demand for proactive brain health tools is increasing
rapidly.

We believe the Ivory team shares our passion and energy to make a difference
and has made impressive progress across both consumer and professional
healthcare markets.  We are excited to partner with them to expand access to
CANTAB Pathway™ in India."

Ivory recently published India's first-of-its-kind Brain Health Report,
providing new insights into the country's cognitive wellbeing landscape.
Multiple studies suggest that up to 90% of cognitive impairment remains
underdiagnosed, highlighting a substantial unmet need for scalable early
screening solutions.

With no definitive cure for neurodegenerative conditions like dementia,
prevention and early identification are increasingly critical.  Ivory's
mission is to shift the focus from late-stage diagnosis to proactive brain
health management through neuroscience-based digital assessments, enabling
individuals to take action before symptoms escalate.

Issac John, Chief Executive Officer - Ivory, said, "Our founding scientists
have known and used CANTAB for many years.  We appreciate the strong
scientific pedigree of the assessments based on thousands of clinical
peer-reviewed papers.  The Cambridge Cognition team have built CANTAB
Pathway™ to be exactly the product we need to add to our offering to enable
us to pursue our mission of shifting the focus from late-stage diagnosis to
proactive brain health solutions."

India has an expanding middle and affluent class, with an estimated 90-190
million people for whom longevity, healthspan, and access to high-quality
healthcare are growing priorities.  In parallel, younger urban populations
are increasingly tech-enabled and motivated to manage their health through
monitoring and lifestyle choices.

Dr. Sumiti Saharan, Chief Scientific Officer, Ivory, said "Early cognitive
screening is one of the most powerful ways to change trajectories in
neurodegenerative conditions, where intervention often begins only after
cognitive decline has already advanced.  In India, under diagnosis of
cognitive impairment remains a significant gap.  Scalable, validated digital
tools such as CANTAB Pathway™ offer an opportunity to standardise
assessment, enable earlier identification and empower clinicians to intervene
at a stage when it can make the greatest difference."

This strategic partnership between Cambridge Cognition and Ivory offers high
accuracy, low burden of administration and real-time results that are
essential to improving early identification of cognitive impairment and
supporting brain health at scale.

Under this agreement, Ivory intends to deploy CANTAB Pathway™ at scale
across both professional healthcare and consumer health segments in India,
leveraging its established and growing clinical network, consumer-facing
platform, and partnerships across hospitals, clinics, and diagnostic and
health-tech ecosystems to expand access to early cognitive screening.  These
flagship assessments are currently available in English and multiple languages
including Hindi, Tamil, Telugu, Bengali and Kannada, with further language
expansion planned.

 

NOTES TO EDITORS

 

ABOUT CAMBRIDGE COGNITION AND CANTAB PATHWAY™

Cambridge Cognition is a neuroscience technology company whose digital
cognitive assessments support scientific discovery, accelerate drug
development and improve patient care.

The Company has developed a suite of touchscreen and voice-based cognitive
assessments delivered under the CANTAB and Winterlight brands.  These
assessments are designed to:

●    require minimal specialist administration

●    deliver objective results in real time or shortly after completion

●    reduce administrator bias

●    support longitudinal monitoring of cognitive function

Assessment results can be presented in formats appropriate for both consumers
in home-use settings and healthcare professionals in clinical or research
environments.

Most of Cambridge Cognition's assessments are available in multiple languages.
Relevant to the Ivory agreement, tasks are currently available in Hindi,
Tamil, Telugu, Bengali and Kannada, with further language expansion under
consideration.

CANTAB Pathway™ is Cambridge Cognition's latest scalable cognitive
assessment solution, structured as an escalating series of tasks for use in
consumer and healthcare settings:

●    CANTAB One™ - a brief assessment of overall cognitive function

●    CANTAB Insight™ - a three-task battery providing deeper insight
across five cognitive sub-domains

●    CANTAB Plus™ - specialist disease-specific modules for use by
appropriately qualified healthcare professionals, covering eight indications
including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease,
schizophrenia, depression, and Alzheimer's disease and related dementias

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

ABOUT IVORY

Nostalgic Dust Private Limited, trading as Ivory, is a pioneering brain health
startup dedicated to early detection and proactive cognitive care.  By
combining neuroscience, neuropsychology, and data-driven interventions, Ivory
empowers individuals to maintain and enhance their cognitive well-being.  The
company offers an FDA-registered cognitive assessment and personalized brain
training programs through its app, helping users track, train, and optimize
their brain health.  Ivory is backed by a Clinical team that comes with 80+
years of experience across multi-disciplinary domains spanning Neuroscience,
Medicine and Neuropsychology.

Founded in October 2022 by Issac John and Rahul Krishnan, Ivory is backed by
leading investors, including Capital A, TDV Partners, and prominent angel
investors.  Ivory has also gained national visibility following its
appearance on Shark Tank India (Season 4) and is a multi-award-winning
company, including most recently being a winner at the Meet the Drapers
Awards. With a mission to bridge the gap between early detection and long-term
brain health, Ivory is shaping the future of preventive healthcare - one mind
at a time.

Website link: https://www.liveivory.com/ (https://www.liveivory.com/)

Enquiries:

 Cambridge Cognition Holdings plc                    Tel: +44 1223 810700 

 Rob Baker, Chief Executive Officer                  press@camcog.com (mailto:press@camcog.com)  

 Ronald Openshaw, Chief Financial Officer

 Adam Michael, Head of Corporate Communications
 Ivory                                               Ivory Press Relations:

 Issac John Co-founder and CEO                       +91 885 019 3264

 Rahul Krishnan, Co-founder and CPO                  issac@liveivory.com
 Panmure Liberum Limited (NOMAD & Joint Broker)      Tel: +44 20 7886 2968

 Will Goode / Mark Rogers / Freddy Crossley          (Corporate Finance)

 Rupert Dearden                                      (Corporate Broking)
 Singer Capital Markets Limited (Joint Broker)       Tel: +44 20 7496 3000

 Amber Higgs / James Serjeant                         

 Daniel Ingram / Asha Chotai

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRBRGDDSUBDGLU



            Copyright 2019 Regulatory News Service, all rights reserved